409179.fig.001a
(a)
409179.fig.001b
(b)
409179.fig.001c
(c)
409179.fig.001d
(d)
409179.fig.001e
(e)
409179.fig.001f
(f)
409179.fig.001g
(g)
409179.fig.001h
(h)
409179.fig.001i
(i)
409179.fig.001j
(j)
409179.fig.001k
(k)
409179.fig.001l
(l)
Figure 1: Representative human prostatic carcinomas showing immunostaining for PSA, PSMA, RKIP, Raf-1, MEK-1, ERK-1, ERK-2, p-Akt (T308), p-Akt (S473), NF-κB p50, and NF-κB p65. High grade prostatic carcinoma stained with hematoxylin/eosin (a). Low PSA immunoreactivity in neoplastic epithelial cells (b). Strong and diffuse cytoplasmic and membranous PSMA expression in infiltrating prostatic malignant cells (c). Immunostaining for RKIP predominantly in the cytoplasm (d). Nuclear immunostaining for Raf-1 in neoplastic epithelial cells (e). Immunostaining for MEK-1 in the nucleus and the cytoplasm (f). ERK-1 showed cytoplasmic and nuclear immunoreactions of epithelial cells (g). Immunostaining for ERK-2 in the nucleus and the cytoplasm of epithelial cells (h). Strong and diffuse p-Akt (T308) expression in cytoplasm of neoplastic acinar structure in prostatic carcinoma (i). p-Akt (S473) showed strong and diffuse cytoplasm and cytoplasmic membranes in infiltrating malignant cells (j). NF-κB p50 immunoreactivity in the nucleus and the cytoplasm (k). NF-κB p65 showed cytoplasmic and nuclear immunoreactions of epithelial cells in prostate cancer (l). Bar: 20 μm.